These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

95 related articles for article (PubMed ID: 2518158)

  • 1. Monthly dosage form of leuprolide approved by FDA.
    Oncology (Williston Park); 1989 Apr; 3(4):139. PubMed ID: 2518158
    [No Abstract]   [Full Text] [Related]  

  • 2. Flutamide approved for prostate cancer.
    Oncology (Williston Park); 1989 Mar; 3(3):135. PubMed ID: 2518157
    [No Abstract]   [Full Text] [Related]  

  • 3. Leuprolide plus flutamide: combined androgen blockade in the treatment of advanced prostate cancer.
    Chodoff L
    Mt Sinai J Med; 1990 May; 57(3):171-3. PubMed ID: 2115128
    [No Abstract]   [Full Text] [Related]  

  • 4. [Treatment of prostatic cancer with slow-release formulation of luteinizing hormone releasing hormone (LH-RH) analog].
    Fuse H; Akimoto S; Akakura K; Shimazaki J; Murakami S
    Hinyokika Kiyo; 1988 Mar; 34(3):555-60. PubMed ID: 3133936
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Zoladex in prostatic carcinoma].
    Di Silverio F; Serio M
    Drugs Exp Clin Res; 1990; 16 Suppl():19-29. PubMed ID: 2150501
    [No Abstract]   [Full Text] [Related]  

  • 6. Metastatic prostate cancer under long term pernasal buserelin or intramuscular decapeptyl depot treatment.
    Wenderoth UK; Spindler HW; Ehrenthal W; von Wallenberg H; Happ J; Jacobi GH
    Prog Clin Biol Res; 1987; 243A():207-20. PubMed ID: 2958851
    [No Abstract]   [Full Text] [Related]  

  • 7. [Clinical efficacy of (D-Leu6)-des Gly-NH2(10)-LHRH ethylamide against prostatic cancer].
    Yamanaka H; Makino T; Kumasaka F; Shida K
    Hinyokika Kiyo; 1984 Apr; 30(4):545-60. PubMed ID: 6435416
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hormonal therapy for prostate cancer.
    Torti FM
    N Engl J Med; 1984 Nov; 311(20):1313-4. PubMed ID: 6436701
    [No Abstract]   [Full Text] [Related]  

  • 9. Evaluation of synthetic agonist analogue of gonadotropin-releasing hormone (leuprolide) on testicular androgen production in patients with carcinoma of prostate.
    Santen RJ; Warner B
    Urology; 1985 Feb; 25(2 Suppl):53-7. PubMed ID: 3918377
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment of metastatic carcinoma of the prostate with leuprolide, an LHRH analogue.
    Smith JA
    Prog Clin Biol Res; 1985; 185A():279-85. PubMed ID: 3929267
    [No Abstract]   [Full Text] [Related]  

  • 11. [LHRH analogs as monthly depot preparations in treatment of advanced prostate cancer].
    Urologe A; 1991 May; 30(3 Suppl):2-3. PubMed ID: 1746071
    [No Abstract]   [Full Text] [Related]  

  • 12. Leuprolide: a review of its effects in comparison with diethylstilboestrol in the treatment of advanced cancer of the prostate.
    Garnick MB; Glode LM; Smith JA; Max DT
    Br J Clin Pract; 1985 Feb; 39(2):73-6. PubMed ID: 3921047
    [No Abstract]   [Full Text] [Related]  

  • 13. Randomised, double-blind study of estramustine phosphate and leuprolide acetate.
    De la Grange AB
    Prog Clin Biol Res; 1987; 243B():227-8. PubMed ID: 3116555
    [No Abstract]   [Full Text] [Related]  

  • 14. [Hormonal and clinical efficacy of (D-Leu6)-des Gly-NH2(10)-LH.RH ethylamide against prostatic cancer].
    Imai K; Kumasaka F; Kobayashi M; Suzuki T; Takahashi O; Yamanaka H
    Hinyokika Kiyo; 1985 Dec; 31(12):2302-6. PubMed ID: 2938456
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical progress with LHRH analogues in prostatic cancer. Proceedings of an international symposium. Monte Carlo, 20 January 1990.
    J Int Med Res; 1990; 18 Suppl 1():1-125. PubMed ID: 2108881
    [No Abstract]   [Full Text] [Related]  

  • 16. Leuprolide: a review of its effects in animals and man.
    Drago JR; Rohner T; Santen R; Manni A; English H; Lipton A; Harvey H
    Br J Clin Pract; 1985 Feb; 39(2):77-9. PubMed ID: 3921048
    [No Abstract]   [Full Text] [Related]  

  • 17. A review of the pharmacokinetic and pharmacological properties of a once-yearly administered histrelin acetate implant in the treatment of prostate cancer.
    Schlegel P
    BJU Int; 2009 Mar; 103 Suppl 2():7-13. PubMed ID: 19228147
    [No Abstract]   [Full Text] [Related]  

  • 18. Pharmaceutical aspects. Nasal and depot formulations of leuprolide.
    Shimamoto T
    J Androl; 1987; 8(1):S14-6. PubMed ID: 3104262
    [No Abstract]   [Full Text] [Related]  

  • 19. [LH-RH treatment of patients with prostatic cancer by subcutaneous injection, non-biodegradable and biodegradable slow delivery system and intranasal spray application].
    Imai K; Saruki K; Totsuka Y; Shimizu N; Yamanaka H; Kitaura K; Tomaru Y; Nakamura T; Koya A; Yazima H
    Nihon Hinyokika Gakkai Zasshi; 1987 Mar; 78(3):411-9. PubMed ID: 3116307
    [No Abstract]   [Full Text] [Related]  

  • 20. Dermatitis herpetiformis associated with administration of a gonadotropin-releasing hormone analog.
    Yu SS; Connolly MK; Berger TG; McCalmont TH
    J Am Acad Dermatol; 2006 Feb; 54(2 Suppl):S58-9. PubMed ID: 16428002
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.